{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:20:56Z","timestamp":1762917656677},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.dsx.2016.01.013","type":"journal-article","created":{"date-parts":[[2016,1,17]],"date-time":"2016-01-17T05:30:31Z","timestamp":1453008631000},"page":"161-165","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Insulin glargine versus insulin degludec in patients failing on oral therapy in type 2 diabetes: A retrospective real world comparative data from India"],"prefix":"10.1016","volume":"10","author":[{"given":"Samit","family":"Ghosal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binayak","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalyan Kumar","family":"Gangopadhyay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dsx.2016.01.013_bib0105","doi-asserted-by":"crossref","first-page":"330","DOI":"10.2337\/diacare.25.2.330","article-title":"Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57)","volume":"25","author":"Wright","year":"2002","journal-title":"Diabetes Care"},{"issue":"Suppl. 3","key":"10.1016\/j.dsx.2016.01.013_bib0110","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.2337\/diabetes.53.suppl_3.S16","article-title":"Five stages of evolving \u2013 cell dysfunction during progression to diabetes","volume":"53","author":"Weir","year":"2004","journal-title":"Diabetes"},{"issue":"Suppl. 1","key":"10.1016\/j.dsx.2016.01.013_bib0115","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.2337\/dc15-S010","article-title":"Approaches to glycemic treatment. Sec. 7. In Standards of Medical Care in Diabetesd2015","volume":"38","author":"American Diabetes Association","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2016.01.013_bib0120","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1124\/pr.110.003319","article-title":"Novel pharmacological approaches to the treatment of type 2 diabetes","volume":"64","author":"Verspohl","year":"2012","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.dsx.2016.01.013_bib0125","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2337\/diacare.28.2.254","article-title":"Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes","volume":"28","author":"Janka","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2016.01.013_bib0130","doi-asserted-by":"crossref","first-page":"389","DOI":"10.7326\/0003-4819-130-5-199903020-00002","article-title":"Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: a randomized, controlled trial","volume":"130","author":"Yki-J\u00e4rvinen","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.dsx.2016.01.013_bib0135","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.2337\/db13-0468","article-title":"Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk","volume":"63","author":"Chow","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.dsx.2016.01.013_bib0140","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.2337\/dc14-0908","article-title":"Association between severe hypoglycemia, adverse macrovascular events, and Inflammation in the Edinburgh Type 2 Diabetes Study","volume":"37","author":"Bedenis","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2016.01.013_bib0145","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","article-title":"The treat-to-target trial randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients","volume":"26","author":"Riddle","year":"2003","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.dsx.2016.01.013_bib0150","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1463-1326.2012.01627.x","article-title":"Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes","volume":"14","author":"Heise","year":"2012","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.dsx.2016.01.013_bib0155","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2016.01.013_bib0160","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1464-5491.2006.01913.x","article-title":"Twice-daily compared with once-daily insulin glargine in people with type 1 diabetes using meal-time insulin aspart","volume":"23","author":"Ashwell","year":"2006","journal-title":"Diabet Med"},{"issue":"10","key":"10.1016\/j.dsx.2016.01.013_bib0165","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/j.1463-1326.2012.01638.x","article-title":"Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes","volume":"14","author":"Heise","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.dsx.2016.01.013_bib0170","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1463-1326.2012.01627.x","article-title":"Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes","volume":"14","author":"Heise","year":"2012","journal-title":"Diabetes Obes Metab"},{"issue":"9825","key":"10.1016\/j.dsx.2016.01.013_bib0175","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(12)60204-9","article-title":"Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomized, open-label, treat-to-target non-inferiority trial","volume":"379","author":"Heller","year":"2012","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.dsx.2016.01.013_bib0180","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4158\/EP13287.OR","article-title":"Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials","volume":"20","author":"Rodbard","year":"2014","journal-title":"Endocr Pract"},{"issue":"4","key":"10.1016\/j.dsx.2016.01.013_bib0185","doi-asserted-by":"crossref","first-page":"858","DOI":"10.2337\/dc12-1668","volume":"36","author":"Meneghini","year":"2013","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.dsx.2016.01.013_bib0190","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40262-013-0113-2","article-title":"Insulin degludec: pharmacokinetics in patients with renal impairment","volume":"53","author":"Kiss","year":"2014","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.dsx.2016.01.013_bib0195","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40261-013-0154-1","article-title":"Insulin degludec: pharmacokinetic properties in subjects with hepatic impairment","volume":"34","author":"Kupcova","year":"2014","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.dsx.2016.01.013_bib0200","first-page":"225","article-title":"Is insulin degludec a more effective treatment for patients using high doses of insulin glargine but not attaining euglycemia? Some case reports from India","volume":"7","author":"Sinha","year":"2014","journal-title":"Diabetes Metab Syndr Obes"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402115300801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402115300801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T19:27:22Z","timestamp":1567538842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402115300801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S1871402115300801"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2016.01.013","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Insulin glargine versus insulin degludec in patients failing on oral therapy in type 2 diabetes: A retrospective real world comparative data from India","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2016.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Diabetes India. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}